Vertex Cuts 78 Jobs at Crinetics San Diego
The layoffs follow Vertex's completed $10 billion acquisition of the San Diego biotech firm, with cuts taking effect in January.
Updated on Nov. 10, 2026 in Biotech

Live Poll
Do you think big company takeovers usually leave workers better off?
Vertex Pharmaceuticals is laying off 78 employees at Crinetics Pharmaceuticals' San Diego headquarters, according to a Work Adjustment and Retraining Notification filed in California. The cuts follow Vertex's September 1 completion of its $10 billion acquisition of Crinetics and take effect in January.
Why it matters
The reductions result from integrating the two businesses after the acquisition, eliminating roles that will not continue in the combined organization. The move signals how acquired biotech operations are being restructured in San Diego as Vertex consolidates the company.
The 78 layoffs represent about 13% of Crinetics' 594 full-time employees as of February 13, 2026. Vertex has not disclosed which functions within the company are being eliminated.
The players
Vertex Pharmaceuticals
Vertex Pharmaceuticals is a Boston-headquartered biotechnology company known for its cystic fibrosis therapies, which acquired Crinetics in a $10 billion deal.
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a San Diego biotechnology company that develops treatments for endocrine disorders and sells Palsonify for acromegaly.
Charles Wagner
Charles Wagner is the chief operating officer of Vertex Pharmaceuticals who is spearheading the integration of Crinetics.
The details
Affected employees are being offered severance, outplacement support, and career counseling. Chief operating officer Charles Wagner is leading the integration of Crinetics into Vertex, which is also reflected in roughly $60 million in Crinetics operating and integration-related expenses reported in September.
Timeline
September 1: Vertex completes its $10 billion Crinetics acquisition.
January: Crinetics layoffs take effect.
November 30: FDA decision date for povitacept.
Market Landscape
Post-acquisition workforce consolidation has become a common step in large biotech deals as acquirers combine overlapping operations. Vertex's cuts at Crinetics follow the same integration playbook used after its major acquisitions.
Affected San Diego workers are receiving severance, outplacement support, and career counseling as they transition out of Crinetics. Vertex's integration could also shape the pace of new Palsonify and atumelnant launches tied to future local research roles.
The takeaway
Acquisitions in biotech often trigger rapid restructuring, so workers at acquired firms should watch integration announcements closely. Readers tracking the sector can follow Vertex's expense guidance and pipeline milestones as the combined company takes shape.
What happens next
Crinetics layoffs take effect in January, and the FDA decision date for povitacept is November 30.
Further reading
For more on the regional industry, see San Diego Biotech coverage.
Source note: This article includes information reported by FiercePharma.
Live Poll
Do you think big company takeovers usually leave workers better off?






